Skip to content
Politically.com Search all
Menu

2026 · 1st Quarter (Jan 1 - Mar 31)

ARDELYX

Filed by THE MCMANUS GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 20, 2026
Income
$60,000.00
Expenses
Not reported
Client
ARDELYX
Filing UUID
d3bd1cee-f980-4a51-9c1c-594e387a6085
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Issues related to the 2025 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule (CMS-105-F), specifically the inclusion of oral-only drugs in the ESRD PPS Bundled Payment. H.R.6214 - Kidney Care Access Protection Act Issues related to Most Favored Nation Drug Pricing Reform

Literal federal measure citations: H.R.6214

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.